The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to provide written informed consent, 3. Diagnosis of SSc, as defined by the 2013 ACR/EULAR classification of SSc64 with a positive ANA 4. Baseline score ≥55 on the FACIT-Fatigue scale, 5. Presence of Raynaud phenomenon with ASRAP-SF severity of T-score ≥40, 6. Steady daily doses and any immunosuppressive medication, vasodilators or other medications used to treat pulmonary hypertension, antidepressants and anxiolytic use for 4 weeks prior to baseline 7. Currently owns and operates an iOS or Android smart phone regularly 8. Ability to comply with the clinical visits schedule and the study-related procedures. Exclusion Criteria: 1. History of sympathectomy or stellate ganglion block 2. History of Botox injections to the digits within the last 3 months 3. Diabetes mellitus 4. Major surgery within 8 weeks 5. Hospitalization for any reason within four weeks of the study baseline visit 6. Active malignancy 7. Pregnant or breastfeeding women, 8. End-stage renal disease (estimated glomerular filtration rate \< 15 mL/min/1.73m2) or on dialysis, 9. Hepatic insufficiency as defined by function worse than Child-Pugh Class B 10. Medication exclusions: 1. actively prescribed standing doses of beta-blockers, 2. actively prescribed standing doses of sedatives, hypnotics, opioids, benzodiazepines or anti-psychotic medications.